Nodality, Inc. and Pfizer have entered a strategic collaboration for the use of Nodality’s Single Cell Network Profiling (SCNP) technology for the development of Pfizer compounds. The multi-year agreement will focus on providing biological bases for streamlining the development of potential Pfizer compounds for autoimmune disease with an initial focus on Lupus, including characterizing mechanisms of action, disease analysis, and drug profiling. Pfizer also has the option to partner with Nodality...